Evidence map›Paper›PMID 42102820›Full record

ArticleCell host & microbe2026

Human neutralizing antibodies targeting the measles virus hemagglutinin and fusion surface proteins.

Marissa Acciani, Dawid Zyla, Gele Niemeyer, Stephanie Harkins, Diptiben Parekh, Emily Pawlack, Davide Lacarbonara, Dhvanir Kansara, Margaret E Ackerman, Stefan Niewiesk and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell host & microbe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marissa AccianiCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Dawid ZylaCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Gele NiemeyerCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA; School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Stephanie HarkinsCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Diptiben ParekhCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Emily PawlackDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.
Davide LacarbonaraDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
Dhvanir KansaraDepartment of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA.
Margaret E AckermanThayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA.
Stefan NiewieskDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.
Matteo PorottoDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Center for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 43210, USA; Department of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, 81100 Caserta, Italy.
Kathryn M HastieCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA. Electronic address: kmhastie@lji.org.
Erica Ollmann SaphireCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA; School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: erica@lji.org.

Funding

ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
Development of therapeutic fusion inhibitor peptides for Measles encephalitisR01NS105699 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO · 2018 to 2022
$1.8M
Thermostable measles fusion glycoprotein as a new vaccine strategyR56AI183536 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO, SAPHIRE, ERICA OLLMANN · 2024 to 2024
$884k
Thermostable measles fusion glycoprotein as a new vaccine strategyR01AI190902 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Matteo Porotto, Erica Ollmann Saphire · 2026 to 2026
$883k
Passive immunotherapy for measles infectionR01AI195589 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Matteo Porotto, Erica Ollmann Saphire · 2026 to 2026
$855k
What is the human antibody response to measles virus vaccination?R21AI180456 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2024 to 2025
$496k
NIAID NIH HHS R01 AI190902NIAID NIH HHS R01 AI195589NIAID NIH HHS R21 AI180456NIAID NIH HHS R56 AI183536NIGMS NIH HHS R01 GM129325NINDS NIH HHS R01 NS105699
6 · The paper itself

Abstract

Measles virus (MeV), a highly transmissible paramyxovirus, can cause severe complications and death, particularly in infants and young children. How and where human antibodies target and neutralize MeV remain unclear. Here, we report a panel of human monoclonal antibodies (mAbs) specific for MeV hemagglutinin (H) and fusion (F) surface proteins, derived from the memory B cells of a Measles-Mumps-Rubella (MMR) vaccinee. We mapped four and five major epitope clusters on H and F, respectively, and structurally characterized representative mAbs from each epitope cluster. MAbs against both H and F offer broad, potent, picomolar-level neutralization and substantially reduce viral loads in vivo when delivered before or after viral exposure. High-resolution cryo-electron microscopy of mAb complexes with H and F reveal highly conserved contact sites of the most protective antibodies. Characterization of these fully human mAbs provides avenues for prophylactic or therapeutic intervention against re-emerging MeV.

Indexed as

Antibodies, NeutralizingAntibodies, ViralHemagglutinins, ViralMeasles virusViral Fusion ProteinsAnimalsAntibodies, MonoclonalCryoelectron MicroscopyEpitope MappingEpitopesHumansMeaslesMemory B CellsMiceAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesHemagglutinins, ViralViral Fusion Proteinsantibodycryo-EMfusionimmunotherapymeaslesneutralizationparamyxovirusstructural biology

Identifiers

PMID42102820
PMCPMC13374049

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.